Hubungan antara Pengetahuan Responden yang Pernah Menderita Hepatitis tentang Perilaku Penularan Hepatitis C dengan Antibodi Anti Hepatitis C (Titer Anti-HCV) di Indonesia
(Relationship Between the Knowledge of Respondents Who Have Had Hepatitis Infection about the Behaviour of Hepatitis C Transmission with Anti Hepatitis C Antibody in Indonesia)
Abstract
Hepatitis C virus (HCV) is a viral disease that becomes the world’s second problem after hepatitis B virus disease. The prevalence of HCV 3% or about 130-170 million people in the world are infected with HCV. In most developed countries the prevalence is below 1%, but in Asian countries the prevalence is higher. The aim of this study was to find the relationship between hepatitis C immunity (anti-HCV titre) behavior from the Riskesdas 2007. Data was a cross-sectional study, by analyzing anti-HCV titre data and data on age, gender and behavioral variables (use of needles injections, use of razors, condom use and sexual behavior). The total number of respondents who were tested for antibodies was 20,648. The reseach was done in March – October 2014. The results of the study of behavioral variables (using a shared razor, using condoms during sex and changing partners) had no significant association with anti hepatitis C antibody titers, while the age variable and syringe use variables had a significant correlation with p = 0.001. The conclusion of this study was that there was no significant relationship between treatment (shared razor use, condom use and changing sex partners) between people who had hepatitis C and anti hepatitis C antibody titers.
Abstrak
Virus Hepatitis C (HCV) merupakan penyakit virus yang menjadi masalah kedua dunia setelah penyakit virus hepatitis B. Prevalensi HCV 3% atau sekitar 130-170 juta orang di dunia terinfeksi HCV. Di sebagian besar negara maju prevalensi di bawah 1%, tetapi di negara-negara Asia prevalensinya lebih tinggi. Tujuan dari penelitian ini untuk mencari hubungan antara pengetahuan responden tentang perilaku penularan hepatitis C dengan kekebalan hepatitis C (titer anti-HCV) dari data Riskesdas 2007. Desain penelitian cross-sectional, dengan menganalisis data titer anti-HCV dan data variabel umur, jenis kelamin dan variabel pengetahuan tentang perilaku (penggunaan jarum suntik, penggunaan pisau cukur, pemakaian kondom, dan perilaku seksual). Total responden yang diperiksa antibodi sebanyak 20.648. Waktu penelitian dilakukan pada bulan Maret sampai Oktober 2014. Hasil penelitian variabel perilaku (penggunaan pisau cukur bersama, menggunakan kondom saat berhubungan seks dan berganti pasangan) tidak ada hubungan yang bermakna dengan titer antibodi anti hepatitis C, sedangkan variabel umur dan variabel penggunaan jarum suntik terdapat hubungan yang bermakna dengan nilai p=0,001. Kesimpulan penelitian ini tidak ada hubungan yang bermakna antara perilaku (penggunaan pisau cukur bersama sama, penggunaan kondom dan berganti ganti pasangan seks) antara orang-orang yang pernah menderita hepatitis C dengan titer antibodi anti hepatitis C.
References
Kementerian Kesehatan RI. Kebijakan program pencegahan dan pengendalian hepatitis dan PISP di Indonesia, disampaikan pada pertemuan koordinasi, sosialisasi, dan advokasi dalam pengendalian hepatitis Provinsi Riau, Pekan Baru, 2-5 Mei 2018.
Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436–41.
Sievert W, Altraif I, Razavi H, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31(Suppl 2):61–80.
Clinical Practice Guidelines. EASL Clinical Practice Guidelines: Management of hepatitis C. Journal of Hepatology. 2011;55:245.
Shepard CW, Finelli L, Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558–67.
World Health Organization. Global blood safety and availability: facts and figures from the 2007 Blood Safety Survey. 2009. Available at: http://www.who.int/bloodsafety /global_database/blood_safety_factsheet_2009.pdf.
Accessed 5 September 2018.
Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatit C virus epidemiology in Europe, Canada and Israel. Liver In 2011; 31(Suppl 2):30–60.
World Health Organization. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44:20–9.
Perz JF, Armstrong GL, Farrington LA, Hutin Y, Bell B. The contribution of hepatitis B virus and hepatitis C virus infections to cirrhosisand primary liver cancer worldwide. J Hepatol 2006; 45:529–38.
Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HUR. Prevalence of hepatitis B and C viral infections in Pakistan:
findings of a nationalsurvey appealing for effective prevention and control measures. EastMediterr Health J 2010; 16(suppl): S15–23.
Badan Litbangkes. Laporan Riskesdas 2007. Jakarta: Kementerian Kesehatan RI; 2008.
Sievert W, Altraif I, Razavi H, et al. A systematic review of hepatit C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; (Suppl 2):61–80.
Holmberg S. Hepatitis C. In: CDC Health Information for International Travel 2012 (yellow book). Oxford, UK: Oxford UniversityPress, 2012:186–7.
IOM (Institute of Medicine). Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington DC: The National Academies Press, 2010.
Arab Republic of Egypt, Ministry of Health and Population National Committee for the Control of Viral Hepatitis. Egyptian nationalcontrol strategy for viral hepatitis 2008–2012. Available at: http://www.pasteurinternational.Org/ip/resource/filecenter/document/01s-000042-0da/nsp-10-april-200 final.pdf. Accessed 5 Januari 2018.
Francisco M. Averhoff, Nancy Glass, and Deborah Holtzman. Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. Clinical Infectious Diseases 2012;55(S1):S10–15.
Simmons. Consesus Proposals for a Unified System of Nomenclatureof Hepatitis C virus Genotypes. Hepatology 2005;42-932-973. 2012;55(S1):S10–15 2012.
